肿瘤细胞治疗研究
英文原题：MASCC/ISOO Clinical Practice Statement: dental evaluation and management prior to treatment for hematologic malignancies and CAR T-cell therapy.
MASCC/ISOO Clinical Practice Statement: dental evaluation and management prior to treatment for hematologic malignancies and CAR T-cell therapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
该 CPS 为临床医生提供了有效牙科清理的策略，改善患者结局并最大限度减少抗癌治疗期间及之后的并发症。
MASCC/ISOO临床实践声明（CPS）旨在为临床医生管理癌症患者口腔问题提供指导。本CPS讨论儿童、成人和老年血液系统恶性肿瘤患者在化疗、造血细胞移植、嵌合抗原受体（CAR）T细胞治疗及其他治疗前的牙科护理，也包括治疗后恢复牙科治疗的最佳时机建议。
该CPS基于对文献的批判性评估制定，随后由MASCC/ISOO口腔护理研究组专家进行结构化讨论。内容以简明要点和表格呈现，便于形成实用手册，指导最佳护理标准。
接受抗癌治疗的患者需要全面牙科评估和治疗。治疗前牙科护理旨在预防口腔感染、病原体全身播散、口腔疼痛、局部刺激及误吸风险，并教育患者保持口腔卫生、管理预期常见口腔并发症。这种预防性措施有助于维持经口进食、减轻疼痛、避免治疗中断、改善生活质量，并可能降低死亡率。本CPS概述牙科评估和治疗的关键注意事项，重点关注重要牙科诊断、操作优先级，以及相对于血液肿瘤治疗的安排时机。
本CPS为临床医生提供有效牙科准备策略，有助于改善患者结局，并减少抗癌治疗期间及治疗后的并发症。对于CAR-T 细胞治疗，细胞减灭治疗前及紧随其后的牙科计划还需考虑额外因素。
A MASCC/ISOO Clinical Practice Statement (CPS) aims to provide clinicians with a guide for managing oral conditions in cancer patients. This CPS addresses dental care prior to chemotherapy, hematopoietic cell transplantation, chimeric antigen receptor (CAR) T-cell therapy, and other treatments for hematologic malignancies in pediatric, adult, and elderly patients. Guidance on optimal timing for resuming dental treatment post-therapy is also included.
This CPS was developed through a critical evaluation of the literature, followed by a structured discussion of a group of leading experts, members of the Oral Care Study Group of MASCC/ISOO. Information is presented in succinct bullet points and a table to create a practical manual on the best standards of care.
Patients undergoing anti-cancer therapy require a thorough dental assessment and treatment. Pre-therapy dental care aims to prevent oral infection, systemic pathogen spread, oral pain, local irritation, and risk of aspiration and to educate patients on oral hygiene and managing the expected common oral complications. This preventive approach supports oral intake, relieves pain, prevents treatment interruptions, enhances quality of life, and potentially reduces mortality. This CPS outlines the essential considerations for the dental evaluation and treatment, focusing on key dental diagnoses, procedural prioritization, and timing relative to the hemato-oncologic therapy.
This CPS provides clinicians with strategies for effective dental clearance, improving patient outcomes and minimizing complications during and after anti-cancer therapy. CAR T-cell therapy introduces additional considerations in the dental treatment plan before and immediately after the cytoreductive therapy.
MEMBER ACCOUNT
登录成功会直接打开下一页。
